Estimating the Survival Rate in Glioblastoma Multiforme Patients who Received a Peptide Vaccine : A Systematic Review and Meta-analysis
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
INTRODUCTION: Glioblastoma Multiforme (GBM) has a poor prognosis, with current treatments providing no advantage in terms of survival. Certain new immunotherapy methods, such as peptide vaccines, have been used in clinical trials. In this meta-analysis, the effectiveness of peptide vaccinations on the survival rate of GBM patients was studied.
METHODS: A comprehensive search was carried out using three electronic databases: PubMed, Scopus, and ISI. The purpose of this research was to assess Overall Survival (OS). The pooled overall one-year and two-year survival rates in GBM with peptide vaccination were calculated using the general inverse variance technique as random effects hazard ratios (HRs). In the study, subgroups of countries were compared with each other. Japan had the highest one-year survival rate, and the US had the highest two-year survival rate.
RESULTS: With 95% Confidence Intervals (CIs), the one-year OS rate in GBM patients treated with peptide vaccination increased significantly, but the two-year survival rate did not increase. As a result, while additional research is needed, it cannot be concluded that it is an effective therapy for GBM.
CONCLUSION: Our study found that while peptide vaccination treatment did not increase second-year survival, it improved first-year survival. More research needs to be done to find effective vaccinebased treatments for GBM that can help patients survive longer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current drug targets - 24(2023), 12 vom: 16., Seite 998-1007 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dashtaki, Masoumeh Eliyasi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancerous gene |
|---|
| Anmerkungen: |
Date Revised 24.10.2023 published: Print Citation Status Publisher |
|---|
| doi: |
10.2174/1389450124666230816114131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360869912 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360869912 | ||
| 003 | DE-627 | ||
| 005 | 20231226083934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389450124666230816114131 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360869912 | ||
| 035 | |a (NLM)37587807 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dashtaki, Masoumeh Eliyasi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Estimating the Survival Rate in Glioblastoma Multiforme Patients who Received a Peptide Vaccine |b A Systematic Review and Meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a INTRODUCTION: Glioblastoma Multiforme (GBM) has a poor prognosis, with current treatments providing no advantage in terms of survival. Certain new immunotherapy methods, such as peptide vaccines, have been used in clinical trials. In this meta-analysis, the effectiveness of peptide vaccinations on the survival rate of GBM patients was studied | ||
| 520 | |a METHODS: A comprehensive search was carried out using three electronic databases: PubMed, Scopus, and ISI. The purpose of this research was to assess Overall Survival (OS). The pooled overall one-year and two-year survival rates in GBM with peptide vaccination were calculated using the general inverse variance technique as random effects hazard ratios (HRs). In the study, subgroups of countries were compared with each other. Japan had the highest one-year survival rate, and the US had the highest two-year survival rate | ||
| 520 | |a RESULTS: With 95% Confidence Intervals (CIs), the one-year OS rate in GBM patients treated with peptide vaccination increased significantly, but the two-year survival rate did not increase. As a result, while additional research is needed, it cannot be concluded that it is an effective therapy for GBM | ||
| 520 | |a CONCLUSION: Our study found that while peptide vaccination treatment did not increase second-year survival, it improved first-year survival. More research needs to be done to find effective vaccinebased treatments for GBM that can help patients survive longer | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a MHC-II-restricted peptides | |
| 650 | 4 | |a Peptide vaccines | |
| 650 | 4 | |a cancerous gene | |
| 650 | 4 | |a glioblastoma multiforme | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Moradi, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Moradi, Yousef |e verfasserin |4 aut | |
| 700 | 1 | |a Farsani, Elham Asadi |e verfasserin |4 aut | |
| 700 | 1 | |a Ghasemi, Sorayya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug targets |d 2000 |g 24(2023), 12 vom: 16., Seite 998-1007 |w (DE-627)NLM113669291 |x 1873-5592 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:12 |g day:16 |g pages:998-1007 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389450124666230816114131 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 12 |b 16 |h 998-1007 | ||